Loading company…
Waiv develops AI-based diagnostic and precision testing tools for digital pathology and oncology.
Waiv develops AI diagnostic tools for digital pathology and oncology, including the RlapsRisk BC test for biomarker analysis and diagnostic workflows. Founded in 2026 and based in Paris, France, it raised USD 33.00 mn on March 9, 2026, led by Alpha Intelligence Capital and OTB Ventures, with 50 Partners, Karista, and Serena participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in